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Of the vast number of pathogens of infectious diseases, 
a special place belongs to viruses. It is no coincidence that 
the World Health Organization has declared the 21st 
century the century of viruses. Over the past 20 years, the 
world has faced epidemics of coronavirus infection: severe 
acute respiratory syndrome (SARS), Middle East 
respiratory syndrome (MERS), and COVID-19; outbreaks 
of avian and swine flu; the spread of Ebola and Zika fever, 
which have become serious challenges to all of humanity. 
Slowly progressing, persistent, and latent viral 
infections, the mortality rate from which exceeds the 
mortality rate from acute infections, pose no less danger. 
Some pathogens (for example, HIV) are characterized by 
long latency periods, high antigenic variability, and the 
ability to affect the immune system up to its complete 
destruction. Other viruses (for example, human herpesvirus 7 
(HHV-7) and cytomegalovirus) may not explicitly manifest 
themselves but become activated due to stress or other 
factors and, by suppressing the immune system, "open the 
gate" for more dangerous viruses. In this regard, research 
and development of new effective antiviral drugs is a 
priority task of medicinal chemistry. 
Benzazines are heterocycles of great potential which, 
due to their interaction with various molecular targets, can 
serve as the most important scaffold for the development of 
effective therapeutic drugs, including those for antiviral 
therapy. This is evidenced by regularly published reviews 
on the biological activity of quinolines, quinoxalines, and 
quinazolines, which, as a rule, are devoted to a specific 
class of compounds and the discussion of various types of 
biological activity. At the same time, no separate review 
articles on the antiviral activity of benzazines can be found. 
Promising directions for the use of quinoline derivatives 
are outlined in a review by Goncharuk et al.1 published in 
2018. The discussion of antiviral activity is limited by data 
on compounds effective against Japanese encephalitis virus 
and HIV. 
Quinoxaline derivatives are the subject of increased 
interest from researchers due to the wide spectrum of their 
biological activity. A 2015 review by Pereira et al.2 noted 
the ability of quinoxalines to inhibit the replication of 
herpes simplex viruses of types 1 and 2 (HSV-1 and 
HSV-2), cytomegalovirus, varicella zoster and shingles 
viruses. Among the quinoxalines, potent inhibitors of HIV-1 
reverse transcriptase activity and HIV-1 replication in 
tissue cultures have been identified. Quinoxalines, the 
target of which is the NS1 protein of influenza virus which 
plays a central role in suppressing the host cell interferon 
response, facilitation of the replication, and spread of the 
virus, are especially represented. Tariq et al.3 provided data 
on the antiHIV activity of quinoxaline derivatives as non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and 
HIV integrase inhibitors as part of a review of the antiviral 
properties of quinoxalines published in 2018. 
In the review by Khan et al. from 20154 devoted to 
derivatives of quinazolines and quinazolinones, there is no 
separate section on antiviral agents; only 3-substituted 
2-phenylquinazolines with antiviral activity are discussed. 
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The review published in 2018 by Alagarsamy et al.5 
contains a section on the antiviral activity of quinazolines 
which supplies data on derivatives active against HIV-1 
and HIV-2, cytomegalovirus, adenovirus type 2, HSV-1, 
tobacco mosaic virus, vaccinia virus; only a few 
compounds with moderate activity against influenza virus 
were reported. 
The purpose of this minireview is to update the data on 
the antiviral activity of benzazine derivatives of quinoline 
(1), quinoxaline (2), and quinazoline (3) (Fig. 1), consider 
potential molecular targets of benzazine antiviral agents, 
and analyze the structure–activity relationship according to 
data published in 2015–2020. 
Quinolines exhibiting 
antiviral activity 
Compounds that are active against HIV-1 have been 
identified among quinoline derivatives. The main targets of 
potential antiHIV drugs are viral proteins involved in the 
intracellular multiplication of HIV (reverse transcriptase, 
integrase, and protease), as well as viral and cellular 
proteins involved in the attachment of viral particles to the 
cell. Thus, bromine- and chlorine-substituted chalcones 4a–e 
(Fig. 2) exhibited a high degree of inhibition of HIV 
reverse transcriptase.6 
Testing of 8-(naphthalen-1-yl)-substituted quinolines 5–8 
(Fig. 3) revealed promising inhibitors of HIV-1 ribo-
nuclease H (RNase H) (Table 1). In vitro studies showed 
that 7-isopropoxy-8-(naphthalen-1-yl)quinoline (5) acts in 
the early stages of viral replication prior to viral assembly 
and budding. Compound 5 inhibits the activity of RNase H 
and binds directly to HIV-1 reverse transcriptase. In 
addition, additive inhibitory activity against pseudotyped 
viruses has been noted when quinoline 5 is competitively 
dosed with the clinically used non-nucleoside reverse 
transcriptase inhibitor (NNRTI) efavirenz. When tested 
against an NNRTI-resistant HIV-1 isolate, compound 5 
showed a 5.1-fold decrease in the half-maximal inhibitory 
concentration (IC50) while the activity of the reference drug 
efavirenz decreased by 7.6. These results indicate that 
quinoline 5 is a potential lead compound in the 
development of new HIV-1 RNase H inhibitors.7 
A wide range of quinoline derivatives 9–11 (Fig. 4) have 
been studied as novel inhibitors of HIV penetration.8 













5 6.7 ± 0.9 8.9 ± 0.6 4.7 ± 1.6 68.5 ± 17.1 14.6 
6 >100 >100 >100 >100 – 
7 61.4 ± 3.3 77.6 ± 10.8 56.6 ± 0.8 95.0 ± 13.1 1.7 
8 12.6 ± 1.6 14.0 ± 0.8 16.8 ± 3.0 69.3 ± 4.9 5.5 
Efa-
virenz 




Figure 3. The structures of quinoline derivatives 5–8. 
* IC50 – half-maximal inhibitory concentration, CC50 – half-maximal 
cytotoxic concentration, SI – selectivity index (CC50/IC50).  
Figure 2. The structures of quinoline derivatives 4a–e and their 
half-maximal inhibitory concentration (IC50) in regards to HIV 














Compound 10a (Fig. 5) showed the highest in vitro 
activity against HIV-1 strains HIV-1VB59 and HIV-
1UG070 in TZM-bl cell lines (IC50 3.35 ± 0.87 and  
2.57 ± 0.71 μM, respectively). Its ability to inhibit entry 
into the target cell (IC50 1.40 ± 0.28 μM, therapeutic index 
Table 1. Activity, cytotoxicity, and selectivity 
of 8-(naphthalen-1-yl)-substituted quinolines 5–8 
against HIV-1 in the TZM-b1 cell line* 
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(TI) 38.29) as well as the process of fusion with the target 
cell (IC50 0.96 ± 0.28 μM, TI 55.83) is given as the 
purported mechanisms of action.8 
triazol-1-yl)-substituted quinolines may be of interest for 
the development of new anti-influenza drugs against OST-
resistant virus strains. 
In recent years, data have appeared on the ability of 
quinoline derivatives 13–15 to inhibit the replication of 
arboviruses such as Zika (ZIKV) and chikungunya 
(CHIKV).10 2,8-Bis(trifluoromethyl)quinoline derivatives 
13a and 14 (Fig. 7, Table 3) showed the highest antiZIKV 
activity (half-maximal inhibitory concentration (EC50) 
Figure 4. The structures of quinoline derivatives 9–11. 
Figure 6. The structures of quinoline derivatives 12a,b. 
Table 2. Efficiency of inhibition of WT and OST-resistant  
influenza strains by compound 12b 





IC50 (OST-resistant strain) / 
IC50 (WT strain) 
12b, μM OST, nM 12b OST 
A/H3N2 WT 19.90 ± 1.3 0.15 ± 0.032   
A/H3N2 E119V 2.60 ± 0.8 4.19 ± 0.16 0.13 27.0 
A/H1N1 WT 3.50 ± 0.9 0.21 ± 0.011   
A/H1N1 H275Y 10.60 ± 0.9 79.94 ± 3.2 3.00 380.0 
B WT 22.00 ± 1.1 16.00 ± 2.9   
B R152 K 30.00 ± 1.6 85.00 ± 5.4 1.40 5.30 
Table 3. Activity, cytotoxicity, and selectivity of 
2,8-bis(trifluoromethyl)quinolines 13–15 in respect to 
replication of ZIKV in the Vero cell line* 
Compound EC50, μM CC50, μM SI 
13a 0.8 ± 0.06 195 ± 8.9 243 
13b 2.0 ± 0.1 287 ± 21 143 
14 0.8 ± 0.03 189 ± 10 236 
15 1.4 ± 0.09 316 ± 27 225 
Mefloquine 3.6 ± 0.3 212 ± 14 58 
* EC50 – half-maximal effective concentration, SI – selectivity index 
(CC50/IC50).  
Figure 7. The structures of quinoline derivatives 13–15. 
Of a number of synthesized 6-(1,2,3-triazol-1-yl)-
substituted quinolones, compounds 12a,b (Fig. 6) were 
identified that are capable of inhibiting the activity of the 
neuraminidase of wild-type influenza virus (WT). It was 
noted that a change in the position of the 1,2,3-triazole 
fragment as well as a decrease in the size of the R 
substituent lead to the loss of anti-influenza activity, 
probably because of disruption of the patterns of 
interaction with targets.9 
Compounds 12a,b at a concentration of 50 μM most 
effectively inhibited neuraminidase of influenza virus 
H3N2 by 89.0 and 94.8%, respectively. For comparison, 
oseltamivir (OST) at the same concentration inhibited 
neuraminidase activity by 100%. A study of the efficacy of 
compound 12b against circulating WT and OST-resistant 
influenza A and B strains showed that quinolone 12b has 
some advantages over OST. Although OST was more 
effective against wild strains, the IC50 values for compound 
12b did not change significantly in the presence of OST 
resistance mutations. Thus, the ratio of IC50 of OST-
resistant strains to IC50 of WT strains in the case of 
compound 12b was 0.13, 3.0, and 1.4 for influenza virus 
strains A (H3N2), A (H1N1), and B, respectively. Similar 
IC50 ratios for OST increased to 27, 380, and 5.3, 
respectively9 (Table 2). These results show that (1,2,3-
Figure 5. The structure of quinoline derivative 10a, a potential 
HIV inhibitor. 
Figure 6. The structures of quinoline derivatives 12a,b. 
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0.8 μM), which is 5 times more effective than mefloquine, 
an antiviral drug approved by the Food and Drug 
Administration (FDA).10a 
A study10b reported that N'-(2-hydroxybenzylidene)-4-oxo-
1,4-dihydroquinoline-3-carbohydrazides 16a–d (Fig. 8) 
showed significant activity in the micromolar concentration 
range against ZIKV and CHIKV compared to ribavirin. 
N-Acylhydrazones 16a–d were nontoxic toward Vero cells, 
compounds 16c,b showed the best selectivity (selectivity 
index (SI) 1409.7 and 631.7 toward ZIKV and CHIKV, 
respectively) (Table 4). 
The synthesized compounds 16a–d were found to have 
antiviral activity both in the early and post-infectious stages 
of the action of ZIKV and CHIKV which makes them 
excellent candidates for the development of antiZIKV and 
antiCHIKV drugs.10b 
Phenotypic screening of 7000 compounds using 
BHK-21 cells infected with dengue virus type 2 (DENV-2) 
revealed quinolones capable of inhibiting DENV-2  
replication. For the lead compounds 17 and 18 (Fig. 9), the 
EC50 for the DENV-2 is 3.9 and 9.2 μM, respectively;
11 
however, the antiviral mechanism of action of these 
compounds is not entirely clear and requires further 
research. 
Diarylpyrazolyl-substituted quinoline 19 (Fig. 10), 
which exhibited higher inhibitory activity against DENV-2 
(IC50 0.81 μM, SI >246.91), compared with ribavirin (IC50 
12.61 μM, SI 4.47) was considered12 as a potential antiviral 
drug against DENV. It was shown that compound 19 also 
effectively inhibits other serotypes of DENV, reduces the 
clinical manifestations of the disease and mortality in mice 
infected with DENV. 
The quinoline skeleton is currently considered as the 
basis for the development of effective antiviral drugs for 
the prevention and treatment of non-polyomyelitis 
enterovirus infection. As a result of the search for drugs 
with direct action on the conservative multifunctional viral 
protein C2 involved in membrane rearrangement, viral 
assembly, and viral RNA replication, compound 20 was 
identified (Fig. 10) demonstrating high broad-spectrum 
antiviral activity against 5 tested strains of non-
polyomyelitis enteroviruses (two EV-D68 strains (USA, 
Kentucky and USA, Missouri), two EV-A71 strains 
(Taiwan, Tainan and USA, Alaska), and one CVB3 strain), 
and also showed high microsomal stability with a half-life 
of 114.7 min13 (Table 5). Research of this kind is a step 
forward in the development of sought-after antiviral drugs 
against non-polyomyelitis enteroviruses. 
Quinoxalines exhibiting 
antiviral activity 
Potential inhibitors of HIV-1 integrase were designed 
and then synthesized based on a created pharmacophore 
model and 3D analysis of quantitative structure–activity 
relationship (3D-QSAR). 2,3-Diaryl-substituted quinoxa-
lines 21a,b (Fig. 11) showed the best antiHIV activity and 
low toxicity (Table 6). It was noted that lipophilic and 
bulky substituents at positions 2 and 3 of the quinoxaline 
fragment increase the activity of compounds 21a,b against 
HIV as compared to unsubstituted quinoxalines or 
quinoxalines with less bulky substituents.14 
Figure 8. The structures of quinoline derivatives 16a–d. 
Compound CC50, μM 
ZIKV CHIKV 
EC50, μM SI EC50, μM SI 
16a 502 ± 4.38 0.76 ± 0.028 660.9 2.85 ± 0.12 176.2 
16b 669 ± 4.33 0.75 ± 0.011 892.9 1.06 ± 0.077 631.7 
16c 1113 ± 6.11 0.79 ± 0.005 1409.7 2.77 ± 0.18 402 
16d 443 ± 5.1 0.81 ± 0.009 547.5 2.7 ± 0.13 164.2 
Ribavirin 297 ± 4.95 3.95 ± 0.095 75.2 2.42 ± 0.49 122 
Table 4. Cytotoxicity, activity, and selectivity  
of compounds 16а–d against ZIKV and CHIKV  
in the Vero cell line 
Figure 9. The structures of fluoroquinolones 17 and 18. 
Figure 10. The structures of quinoline derivatives 19 and 20. 
Strain CC50, μM EC50, μM SI 
EV-A71 32.4 ± 4.1     
Taiwan, Tainan   31 ± 1.0 10 
USA, Alaska   3.6 ± 0.2 9 
EV-D68 32.4 ± 4.1   
USA, Kentucky/14-18953   0.2 ± 0.1 162 
USA, Missouri/14-18947   0.1 ± 0.02 324 
CVB3 40.1 ± 13.2 0.2 ± 0.2 200 
Table 5. Cytotoxicity, activity, and selectivity of compound 20 
against non-polyomyelitis enteroviruses EV-A71, EV-D68, and 
CVB3 in the RD cell line 
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Virtual library screening, molecular docking, and 3D-
QSAR study allowed the structure to be optimized 
followed by synthesis of quinoxalines 22 and 23 (Fig. 12) 
which showed high antiviral activity against wild and 
mutant (K103N) HIV reverse transcriptase. Compound 22 
showed higher EC50 and SI values compared to the 
commercial drug nevirapine.15 
Quinoxalines 24a,b and 25a,b were identified to have 
low toxicity and high activity in the micromolar 
concentration range (0.06–3.8 μM) against Coxsackie B5 
(CV-B5) enterovirus (Fig. 13). It is assumed that the 
mechanism of action of the obtained compounds is similar 
to that of the group of rhinovirus inhibitors (pleconaril and 
vapendavir), namely, inhibition of the VP1 virus capsid 
protein and preventing its attachment to the host cell.16 
The structure–activity analysis shows that for the 
selective activity to be manifested, the carboxyl group in 
compounds 24a,b and 25a,b must be located in the para 
position of the benzene or pyridyl fragment with respect to 
the sulfanyl group. Compound 24a which showed the highest 
activity against the CV-B5 virus (EC50 0.09 ± 0.01 μM) 
was chosen as the lead compound.16 Given the high activity 
in combination with low cytotoxicity, quinolines 24a,b 
and 25a,b can serve as the basis for the development of 
new drugs for treatment of infections caused by 
enteroviruses. 
Figure 11. The structures of quinoxaline derivatives 21a,b. 
Table 6. AntiHIV activity and cytotoxicity of 
compounds 21a,b in the cell lines MT-4 and Vero 
Compound 
Strain IIIB HIV-1 in MT-4 cells Vero 
IC50, mg/ml CC50, mg/ml 
Protection  
from HIV, % 
CC50, mg/ml 
21a >11.78 11.78 3 >100 
21b >15.45 15.45 3 >100 
Nevirapine 0.075 4.00 – >100 
Zidovudine 0.002 2.00 – – 
Lamivudine 0.58 20.00 – – 
Didanosine 17.95 50.00 – – 
Paclitaxel – – – >100 
Figure 13. The structure of quinoxaline derivatives 24a,b 
and 25a,b, their activity and selectivity against the CV-B5 in the 
Vero cell line (for pleconaril EC50 0.005 ± 0.001 μM). 
Figure 14. The structures of quinazoline derivatives 26a,b. 
Figure 12. Structures of quinoxaline derivatives 22 and 23 and 
their activity, cytotoxicity, and selectivity for HIV in the MT-2 
cell line (for nevirapine EC50 6.7 (4.0–11.3) nM, CC50 96171 
(154165–170754) nM, SI 14353). The EC50 and CC50 values are 
indicated as mean values, the range of values with a confidence 
level of 95% is indicated in parentheses. 
Quinazolines exhibiting 
antiviral activity 
Data on 4-substituted quinazolines with antiviral activity 
are limited to isolated examples. 2-Sulfanylquinazolines 
26a,b containing the chalcone fragment (Fig. 14) (EC50 
156.4 and 138.1 μg/ml, respectively) are superior to 
ribavirin (EC50 436.0 μg/ml) in activity against tobacco 
mosaic virus.17 
A number of 4-arylaminoquinazolines 27a–d effectively 
suppress the replication of human cytomegalovirus.18 
Conjugates 28a,b and 29a,b of 4-arylaminoquinazolines 
with the sesquiterpene lactone artemisinin were synthesized 
(Fig. 15) exhibiting antimalarial action. It was shown that 
derivatives 28a,b and 29a,b are superior in anti-
cytomegalovirus activity to ganciclovir.18b 
The antiviral activity of 2-substituted quinazolinones 30 
obtained by cycloaddition of C-(diethoxyphosphoryl)-
N-methylnitrone 31 to 3-substituted 2-vinylquinazolin- 
(3H)-ones 32 in regards to a wide range of DNA and RNA 
viruses was studied. Several derivatives were active against 
two types of varicella zoster virus (TK+ and TK–) with EC50 
values of 5.4–13.6 µM, as well as against human 
cytomegalovirus (EC50 8.94–13.2 µM)
19 (Table 7). 
3-Aryl- and 3-benzyl-substituted compounds 30b–i are 
superior in activity against the TK– (07-1) strain of 
varicella zoster virus compared to reference drugs 
acyclovir and brivudine (EC50 39.2 and 31.9 μM, 
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respectively); in this case, activation by a viral enzyme is 
required. At the same time, the activity of quinazolinones 
30b–i against the TK+ (OKA) strain was found to be 360–
587 times lower than that of the above reference drugs.19 It 
was noted that 6-bromo-substituted 2-isoxazolidinylquina-
zolin-4(3H)-ones are superior in activity to analogs without 
Figure 15. Structures of quinazoline derivatives 27–29 and their activity against human cytomegalovirus (laboratory strain AD169-GFP) 
(for ganciclovir, EC50 2.60 ± 0.50 μM). 
Compound X R 
EC50, μM EC50, μM 
Varicella zoster virus Human cytomegalovirus 
ТK+ strain (ОKА) ТK– strain (07-1) AD-169 strain Davis strain 
cis-30a Br H >100 >100 >100 100 
trans-30a Br H >100 66.87 >100 >100 
trans-30b Br Bn 13.5 ± 7.1 13.6 ± 9.1 20 20 
trans-30c Br 2-O2NC6H4CH2 10.3 ± 1.1 5.4 ± 1.0 >20 15.29 
trans-30d Br 3-O2NC6H4CH2 8.3 ± 1.4 5.8 ± 1.4 10.4 ± 0.8 11.6 ± 2.5 
trans-30e Br 4-O2NC6H4CH2 6.84 7.51 >20 >20 
trans-30f:cis-30f, 95:5 Br 2-FC6H4CH2 7.76 9.56 8.94 8.94 
trans-30g Br 3-FC6H4CH2 11.6 ± 5.3 7.7 ± 6.2 10.5 ± 2.2 8.94 ± 0 
trans-30h Br 4-FC6H4CH2 12.6 ± 2.6 7.5 ± 5.4 12.5 ± 3.9 13.2 ± 3.1 
trans-30i:cis-30i, 92:8 Br 2,4-F2C6H3CH2 8.7 ± 3.2 10.5 ± 0.3 9.4 ± 0.46 9.7 ± 1.1 
trans-30j Br Me >4 >4 >20 >100 
trans-30k Br Et >20 >20 >20 44.72 
trans-30l H 2-O2NC6H4CH2 46.47 100 >100 44.72 
trans-30m:cis-30m, 9:1 H 4-O2NC6H4CH2 34.20 42.87 44.72 20 
trans-30n:cis-30n, 9:1 H 2-FC6H4CH2 6.84 >10   
trans-30o H 4-FC6H4CH2 15.29 >20   
trans-30p:cis-30p, 97:3 H 2,4-F2C6H3CH2 9.44 >20   
trans-30q H Et 38.80 41.57   
trans-30r:cis-30r, 9:1 H Bn   44.72 >20 
trans-30s H 3-FC6H4CH2   >100 27.59 
Acyclovir   1.55 ± 1.0 39.2 ± 3.6   
Ganciclovir     16.9 ± 6.9 7.7 ± 0.9 
Brivudine   0.023 ± 0.008 31.9 ± 16.1   
Cidofovir     1.5 ± 0.2 1.7 ± 0.4 
Table 7. Activity of 2-isoxazolidinyl-substituted quinazolin-4(3H)-ones 30a–s 







27a R1 = Me, R2 = I, R3 = H
(EC50 1.77 ± 0.19 M)
b R1 = Me, R2 = Cl, R3 = H
(EC50 3.11 ± 0.11 M)
c R1 = H, R2 = R3 = Cl
(EC50 2.01 ± 0.10 M)
d R1 = NO2, R
2 = R3 = Cl


















28a X = OC(O), n = 2 (EC50 0.86 ± 0.20 M)

















29a X = OC(O), n = 2 (EC50 0.21 ± 0.12 M)
b X = CH2, n = 0 (EC50 0.15 ± 0.05 M)
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a substituent in the benzene ring.20 Compounds 30d,f–i are 
comparable in activity against AD-169 and Davis strains of 
human cytomegalovirus (EC50 8.94–13.2 μM) to ganciclovir 
(EC50 16.9 and 7.7 μM) but inferior to cidofovir (EC50 1.5 
and 1.7 μM)19 (Table 7). 
Based on 1-allylquinazoline-2,4-diones containing 
substituted benzoyl or benzyl groups at position 3, 
isoxazolidine derivatives 33 and 34 were obtained (Fig. 16) 
which showed high activity against varicella zoster virus 
and human cytomegalovirus.21 
Figure 16. Structures of quinazoline derivatives 33 and 34 and 
their activity against varicella zoster virus and human 
cytomegalovirus. 
Table 8. Cytotoxicity, activity, and selectivity of quinazoline 
derivatives 35a–c in relation to 
hepatitis B virus in the HepG2 cell line 
Compound 
Testing 
in lamivudine-sensitive  
HepG2 2.2.15 cells 
Testing of lamivudine- 
and entecavir-resistant  







IC50, mM SI IC50, mM SI 
35a 71.51 4.07 17.57     
35b 21.13 1.54 13.72 26.72 1.90 14.06 
35c 15.79 0.71 22.24 17.98 0.84 21.40 
Lamivudine >100 <0.1 >1000 >100 >100 <1 
It was found that derivatives of 6-iodo-3-(3-trifluoro-
methylphenyl)quinazolin-4(3H)-ones containing thiosemi-
carbazone, pyrazole, or azomethine fragments in position 2 
have weak or moderate activity against H5N1 influenza 
virus and are inferior to the reference drug zanamivir.22 
A wide range of 2-benzylsulfanyl-3-(thiophen-2-yl-
methyl)quinazolin-4(3H)-ones were studied, and it was 
shown that compounds 35a–c (Fig. 17) are the most 
promising for the development of non-nucleoside drugs on 
their basis for the treatment of hepatitis B23 (Table 8). 
3-Hydroxy-6-(1,2,3-triazolyl)quinazoline-2,4(1H,3H)-
diones 36a,b (Fig. 18) were obtained by copper(I)-
catalyzed 1,3-dipolar cycloaddition of an alkyne to an 
azide. (4-Nitrophenyl)-substituted derivative 36a outperforms 
cidofovir in activity against vaccinia virus 15 times, while 
4-methoxy derivative 36b outperforms the reference drugs 
against type 2 adenovirus.24 
Quinazolines which are promising for the development 
of anti-influenza agents were reported25 for the first time. 
Such heterocycles were obtained as bioisosteres of indoles 






















R1 = Ph, 2-FC6H4, 3-FC6H4, 4-FC6H4; R




Varicella zoster virus (TK+, TK–): EC50 6.0–21.4 M
34
Varicella zoster virus (TK+, TK–): EC50 3.0–27.1 M
Human cytomegalovirus: EC50 3.0–13.1 M
Figure 17. The structures of quinazoline derivatives 35a–c. 
activity relationship against influenza A/WSN/33 (H1N1) 
virus was analyzed for 2-(quinazolin-4-yl)oxy-N-aryl-
acetamides and N-[(quinazolin-4-yl)oxyethyl]arylamides, 
Figure 18. Structures of 3-hydroxy-6-(1,2,3-triazolyl)quinazoline-
2,4(1H,3H)-diones 36a,b and their activity and selectivity against 
vaccinia virus (comparison drugs brivudine and cidofovir) and 
adenovirus type 2 (comparison drugs cidofovir, zalcitabine, and 
alovudine). 
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Figure 19. The structures of quinazoline derivatives 37–43. 
Compound IC50, μM CC50, μM SI 
37 3.70 ± 0.82 > 100 >27.03 
38 8.64 ± 1.76 > 100 >11.57 
39 4.19 ± 0.43 > 100 >23.87 
40 7.18 ± 1.89 > 100 >13.93 
41a 1.88 ± 0.10 23.28 ± 2.91 12.38 
41b 1.29 ± 0.01 59.94 ± 3.04 46.46 
41c 9.04 ± 0.57 15.86 ± 0.58 1.75 
42a 3.88 ± 0.47 36.64 ± 2.24 9.44 
42b 3.43 ± 0.54 > 100 >29.15 
43a 6.84 ± 0.68 29.43 ± 0.95 4.30 
43b 3.83 ± 0.15 > 100 >26.11 
43c 5.00 ± 1.37 > 100 >20.00 
43d 11.47 ± 0.54 > 100 >8.72 
Ribavirin 15.36 ± 0.93 > 100 >6.51 
Table 9. Activity, cytotoxicity, and selectivity of 2,4-disubsti-
tuted quinazolines 37–43 in relation to influenza A/WSN/33 
(H1N1) virus in the cell line HEK293T-Gluc 
Figure 20. The structures of 2-(thiophen-2-yl)-2,3-dihydro-
quinazolin-4(1H)-ones 44. 
To conclude, quinoline and quinoxaline derivatives are 
active against a large number of RNA viruses. Quinolines 
and quinoxalines are of interest for the development of 
drugs that block one of the stages of HIV life cycle. Among 
them, new inhibitors of reverse transcriptase, RNase H and 
HIV integrase, as well as inhibitors of HIV penetration into 
the target cell have been identified. Quinolines and 
quinoxalines have also been found to be active against 
RNA viruses such as arboviruses and enteroviruses. 
Quinoline derivatives are promising for the development of 
new anti-influenza drugs against oseltamivir-resistant virus 
strains. 
Quinazolin-4-one derivatives are characterized by 
activity against DNA viruses: adenovirus, hepatitis B virus, 
varicella zoster virus, and cytomegalovirus. Apparently, the 
structural similarity with purines determines the ability to 
inhibit DNA polymerase in the same way as acyclovir. 
Recently, successful examples of the design of anti-
influenza agents based on 4-substituted quinazolines are 
noted. 
The data presented in the review indicate the enormous 
potential of benzazines in the design of drugs suitable for 
the treatment of diseases caused by RNA and DNA viruses. 
 
This work was supported by the Ministry of Science and 
Higher Education of the Russian Federation (project No. 
FEUZ-2020-0058 (N687.42B.223/20)). 
as well as their thia and aza analogs. The best results were 
shown by derivatives 37–43 (Fig. 19) which were superior 
in activity to ribavirin (Table 9). It was noted that 
derivatives of S-acetamides are inferior in activity to the 
corresponding N-acetamide derivatives.26 
2-(Thiophen-2-yl)-2,3-dihydroquinazolin-4(1H)-ones 44 
(Fig. 20) demonstrated high activity against human 
cytomegalovirus and polyoma virus.27 
The presented data clearly illustrate the trends in the 
design of quinazoline antiviral agents and summarize 
information on the nature of groups that are advisable to be 
introduced into 2,3- and 2,4-disubstituted quinazolines as 
well as quinazoline-2,4-diones to obtain active derivatives. 
Chemistry of Heterocyclic Compounds 2021, 57(4), 374–382 
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